In a small cohort, Thomas Zeller, Universitäts-Herzzentrum, Bad Krozingen, Germany, and colleagues, investigated the use of the Proteus embolic capture angioplasty balloon for peripheral vascular disease. They reported on their initial experience using the angioplasty balloon in a study published in the Journal of Endovascular Therapy.
The Society for Cardiovascular Angiography and Interventions (SCAI) has released a statement in response to a study showing that minimally invasive procedures significantly lower health payer costs and result in fewer missed workdays when compared to open surgery. The study by Andrew J. Epstein, PhD, et al was published online ahead of print in Journal of the American Medical Association (JAMA) Surgery.
El tratamiento con células de médula ósea autólogas podría reducir las amputaciones en los pacientes con isquemia de miembros inferiores crítica (IMIC).
Gore has announced the US and European launch of lower profile contralateral leg components for the Gore Excluder AAA Endoprosthesis used to treat abdominal aortic aneurysms.
New research provides early evidence that “good” cholesterol may possess anti-aneurysm forming properties. In laboratory-based investigations, scientists found that increased levels of high-density lipoproteins (HDL) blocked the development of aortic aneurysms.
On 4 March 2013, Tenaxis Medical, a medical device company focused on the development of functionally designed surgical sealants, has received FDA approval to bring its innovative ArterX Surgical Sealant to the market. The company plans to start commercialisation of ArterX in the United States early in 2013.
Boston Scientific announced, on the 6 March 2013 the launch of its 0.035 and 0.018 Rubicon Support Catheter in the USA. The device is designed to assist physicians with placement and support of guidewires that are used in peripheral vascular procedures to deliver stents and balloons to open blockages in the legs and other peripheral arteries. Boston Scientific is also launching the 0.035 Rubicon Support Catheter in Europe after the launch of the 0.018 size that was introduced in that region last autumn.
Bolton Medical on 1 March, 2013 announced the Treovance Abdominal Stent-Graft with Navitel Delivery System received CE mark and its international launch. This device will provide physicians with a device indicated for the endovascular treatment of abdominal aortic aneurysms in patients with a proximal neck length of up to 10mm or an infrarenal neck angle up to 75 degrees, according to the company.
In contrast to the commonly adopted surveillance intervals in current abdominal aortic aneurysm screening programmes, surveillance intervals of several years may be clinically acceptable for the majority of patients with small aneurysms, as the smallest aneurysms often do not appear to change significantly over many years, according to a meta-analysis of previous studies reported in the 27 February issue of the Journal of the American Medical Association (JAMA).
With more than 100 patients enrolled, Cook Medical has exceeded 50 percent enrollment in the Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions trial. The first-of-its-kind, prospective, multicenter study is evaluating the retrograde tibiopedal vascular access technique for treating critical limb ischemia (CLI), a manifestation of peripheral arterial disease (PAD).
The New England Journal of Medicine has published findings from the RE-MEDY and RE-SONATE trials investigating dabigatran etexilate (Pradaxa, Boehringer Ingelheim) in the long-term prevention of deep vein thrombosis (DVT) or pulmonary embolism (PE). The results demonstrate that Pradaxa 150mg twice daily is an effective option with a favourable safety profile for the extended prevention of recurrence of these venous blood clots after a first event.
Los bebés nacidos de mujeres obesas típicamente presentan un engrosamiento de un vaso sanguíneo clave del corazón que parece relacionares con el peso excesivo de sus madres
Bolton Medical has selected Expect Advertising for the launch of their new product, Relay Thoracic Stent-Graft. Expect Advertising will develop strategic planning, branding, ad campaign, website, tradeshow, collaterals, SEO, direct marketing, physician/patient education material, and other integrated marketing initiatives for the launch of Relay.
Endologix, Inc. (ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of the CE (Conformite Europeenne) Mark of the Nellix(R) EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms ("AAA"). Nellix is the first available endovascular aneurysm sealing ("EVAS") system. EVAS with Nellix is an advanced treatment strategy designed to simplify endovascular AAA procedures, treat a broad range of patients, and provide enhanced clinical outcomes. The Nellix System is not approved in the United States for either investigational use or commercial sale.
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that data from the first prospective, multicenter, randomized clinical trial of a totally percutaneous approach (PEVAR) to endovascular abdominal aortic aneurysm repair (EVAR) was recently presented at two medical meetings. The presentation on the closure device independent substudy was made by Zvonimir Krajcer, MD (Program Director - Peripheral Vascular Interventions, Department of Cardiology, St. Luke s Episcopal Hospital at the Texas Heart Institute, Houston, TX) at the 25th Annual International Symposium on Endovascular Therapy (ISET), which took place January 19-23, 2013. The presentation on the PEVAR Trial primary analysis was made by Peter R. Nelson, MD, MS (Assistant Professor of Vascular Surgery at University of Florida, Gainesville, FL) at the 37th Annual Meeting of the Southern Association for Vascular Surgery (SAVS), which took place January 23-26, 2013.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos